Prucalopride is an orally-available, dibenzofuran-based, enterokinetic agonist of the human serotonin 5-HT4a and 5-HT4b receptor isoforms with Ki estimates of 3 nM and 8 nM, respectively. It has modest selectivity over the human D4 receptor (2.3 uM), mouse 5-HT3 receptor (3.7 uM) and human s1 receptor (3.7 uM). (1, 2)

Initial tolerability studies show that prucalopride does not encounter cardiotoxicity issues to the extent seen in other drugs of this class. [3]